October 6, 2008
The deal will add Erbitux, a treatment for colorectal and head and neck cancers, to Lilly's portfolio of cancer drugs.
New York-based ImClone had previously rejected two lower-priced takeover offers from Bristol-Myers Squibb Co., its marketing partner for Erbitux.
ImClone says its chairman, Carl Icahn, has agreed to vote in favor of the Lilly deal.
Lilly said in a statement the ImClone addition helps it meet challenges posed by several looming patent expirations. The drug maker loses patent protection on its top-seller, the anti-psychotic Zyprexa, in 2011.
(Copyright 2008 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)
Copyright © 2014, WXIN-TV, Indianapolis